Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 73 entries
Sorted by: Best Match Show Resources per page
Influence of Oral Progesterone Administration on Drug-Induced QT Interval Lengthening: A Randomized, Double-Blind, Placebo-Controlled Crossover Study.

JACC. Clinical electrophysiology

Tisdale JE, Jaynes HA, Overholser BR, Sowinski KM, Flockhart DA, Kovacs RJ.
PMID: 28451647
JACC Clin Electrophysiol. 2016 Dec;2(7):765-774. doi: 10.1016/j.jacep.2016.02.015.

OBJECTIVES: We tested the hypothesis that oral progesterone administration attenuates drug-induced QT interval lengthening.BACKGROUND: Evidence from preclinical and human investigations suggests that higher serum progesterone concentrations may be protective against drug-induced QT interval lengthening.METHODS: In this prospective, double-blind, crossover...

Cite
Tisdale JE, Jaynes HA, Overholser BR, et al. Influence of Oral Progesterone Administration on Drug-Induced QT Interval Lengthening: A Randomized, Double-Blind, Placebo-Controlled Crossover Study. JACC Clin Electrophysiol. 2016;2(7):765-774doi: 10.1016/j.jacep.2016.02.015.
Tisdale, J. E., Jaynes, H. A., Overholser, B. R., Sowinski, K. M., Flockhart, D. A., & Kovacs, R. J. (2016). Influence of Oral Progesterone Administration on Drug-Induced QT Interval Lengthening: A Randomized, Double-Blind, Placebo-Controlled Crossover Study. JACC. Clinical electrophysiology, 2(7), 765-774. https://doi.org/10.1016/j.jacep.2016.02.015
Tisdale, James E, et al. "Influence of Oral Progesterone Administration on Drug-Induced QT Interval Lengthening: A Randomized, Double-Blind, Placebo-Controlled Crossover Study." JACC. Clinical electrophysiology vol. 2,7 (2016): 765-774. doi: https://doi.org/10.1016/j.jacep.2016.02.015
Tisdale JE, Jaynes HA, Overholser BR, Sowinski KM, Flockhart DA, Kovacs RJ. Influence of Oral Progesterone Administration on Drug-Induced QT Interval Lengthening: A Randomized, Double-Blind, Placebo-Controlled Crossover Study. JACC Clin Electrophysiol. 2016 Dec;2(7):765-774. doi: 10.1016/j.jacep.2016.02.015. PMID: 28451647; PMCID: PMC5403156.
Copy Download .nbib Format: NLM
Cytochrome P450 3A4*22, PPAR-α, and ARNT polymorphisms and clopidogrel response.

Clinical pharmacology : advances and applications

Kreutz RP, Owens J, Jin Y, Nystrom P, Desta Z, Kreutz Y, Breall JA, Li L, Chiang C, Kovacs RJ, Flockhart DA.
PMID: 24353446
Clin Pharmacol. 2013 Dec 09;5:185-92. doi: 10.2147/CPAA.S53151. eCollection 2013.

Recent candidate gene studies using a human liver bank and in vivo validation in healthy volunteers identified polymorphisms in cytochrome P450 (CYP) 3A4 gene (CYP3A4*22), Ah-receptor nuclear translocator (ARNT), and peroxisome proliferator-activated receptor-α (PPAR-α) genes that are associated with...

Cite
Kreutz RP, Owens J, Jin Y, et al. Cytochrome P450 3A4*22, PPAR-α, and ARNT polymorphisms and clopidogrel response. Clin Pharmacol. 2013;5:185-92doi: 10.2147/CPAA.S53151.
Kreutz, R. P., Owens, J., Jin, Y., Nystrom, P., Desta, Z., Kreutz, Y., Breall, J. A., Li, L., Chiang, C., Kovacs, R. J., & Flockhart, D. A. (2013). Cytochrome P450 3A4*22, PPAR-α, and ARNT polymorphisms and clopidogrel response. Clinical pharmacology : advances and applications, 5185-92. https://doi.org/10.2147/CPAA.S53151
Kreutz, Rolf P, et al. "Cytochrome P450 3A4*22, PPAR-α, and ARNT polymorphisms and clopidogrel response." Clinical pharmacology : advances and applications vol. 5 (2013): 185-92. doi: https://doi.org/10.2147/CPAA.S53151
Kreutz RP, Owens J, Jin Y, Nystrom P, Desta Z, Kreutz Y, Breall JA, Li L, Chiang C, Kovacs RJ, Flockhart DA. Cytochrome P450 3A4*22, PPAR-α, and ARNT polymorphisms and clopidogrel response. Clin Pharmacol. 2013 Dec 09;5:185-92. doi: 10.2147/CPAA.S53151. eCollection 2013. PMID: 24353446; PMCID: PMC3862586.
Copy Download .nbib Format: NLM
Two-axis bend measurement with Bragg gratings in multicore optical fiber.

Optics letters

Flockhart GM, MacPherson WN, Barton JS, Jones JD, Zhang L, Bennion I.
PMID: 12659255
Opt Lett. 2003 Mar 15;28(6):387-9. doi: 10.1364/ol.28.000387.

We describe what is to our knowledge the first use of fiber Bragg gratings written into three separate cores of a multicore fiber for two-axis curvature measurement. The gratings act as independent, but isothermal, fiber strain gauges for which...

Cite
Flockhart GM, MacPherson WN, Barton JS, et al. Two-axis bend measurement with Bragg gratings in multicore optical fiber. Opt Lett. 2003;28(6):387-9doi: 10.1364/ol.28.000387.
Flockhart, G. M., MacPherson, W. N., Barton, J. S., Jones, J. D., Zhang, L., & Bennion, I. (2003). Two-axis bend measurement with Bragg gratings in multicore optical fiber. Optics letters, 28(6), 387-9. https://doi.org/10.1364/ol.28.000387
Flockhart, G M H, et al. "Two-axis bend measurement with Bragg gratings in multicore optical fiber." Optics letters vol. 28,6 (2003): 387-9. doi: https://doi.org/10.1364/ol.28.000387
Flockhart GM, MacPherson WN, Barton JS, Jones JD, Zhang L, Bennion I. Two-axis bend measurement with Bragg gratings in multicore optical fiber. Opt Lett. 2003 Mar 15;28(6):387-9. doi: 10.1364/ol.28.000387. PMID: 12659255.
Copy Download .nbib Format: NLM
Single isomer versus racemate: is there a difference? Clinical comparisons in allergy and gastroenterology.

CNS spectrums

Flockhart DA, Nelson HS.
PMID: 15131489
CNS Spectr. 2002 Apr;7(4):23-7. doi: 10.1017/s109285290002856x.

Many commonly prescribed drugs exist as a mixture of two distinct chiral isomer forms (enantiomers), each with its own unique chemistry, receptor affinity, and pharmacokinetic profile. Much is unknown concerning the clinical utility of these single enantiomers. This review...

Cite
Flockhart DA, Nelson HS. Single isomer versus racemate: is there a difference? Clinical comparisons in allergy and gastroenterology. CNS Spectr. 2002;7(4):23-7doi: 10.1017/s109285290002856x.
Flockhart, D. A., & Nelson, H. S. (2002). Single isomer versus racemate: is there a difference? Clinical comparisons in allergy and gastroenterology. CNS spectrums, 7(4), 23-7. https://doi.org/10.1017/s109285290002856x
Flockhart, David A, and Nelson, Harold S. "Single isomer versus racemate: is there a difference? Clinical comparisons in allergy and gastroenterology." CNS spectrums vol. 7,4 (2002): 23-7. doi: https://doi.org/10.1017/s109285290002856x
Flockhart DA, Nelson HS. Single isomer versus racemate: is there a difference? Clinical comparisons in allergy and gastroenterology. CNS Spectr. 2002 Apr;7(4):23-7. doi: 10.1017/s109285290002856x. PMID: 15131489.
Copy Download .nbib Format: NLM
Application of free-radical chromogens to determination of nitrite and nitrate ions by EPR spectrometry.

Talanta

Tsang EP, Burns DT, Flockhart BD.
PMID: 18965570
Talanta. 1992 Nov;39(11):1561-7. doi: 10.1016/0039-9140(92)80142-z.

Various azines and substituted phenylene diamines are oxidized by the nitrite ion to give stable radicals in an autocatalytic reaction. This finding has now been developed into highly sensitive methods for nitrite determination by EPR spectrometry. Thus, when the...

Cite
Tsang EP, Burns DT, Flockhart BD. Application of free-radical chromogens to determination of nitrite and nitrate ions by EPR spectrometry. Talanta. 1992;39(11):1561-7doi: 10.1016/0039-9140(92)80142-z.
Tsang, E. P., Burns, D. T., & Flockhart, B. D. (1992). Application of free-radical chromogens to determination of nitrite and nitrate ions by EPR spectrometry. Talanta, 39(11), 1561-7. https://doi.org/10.1016/0039-9140(92)80142-z
Tsang, E P, et al. "Application of free-radical chromogens to determination of nitrite and nitrate ions by EPR spectrometry." Talanta vol. 39,11 (1992): 1561-7. doi: https://doi.org/10.1016/0039-9140(92)80142-z
Tsang EP, Burns DT, Flockhart BD. Application of free-radical chromogens to determination of nitrite and nitrate ions by EPR spectrometry. Talanta. 1992 Nov;39(11):1561-7. doi: 10.1016/0039-9140(92)80142-z. PMID: 18965570.
Copy Download .nbib Format: NLM
Influence of paraoxonase-1 Q192R and cytochrome P450 2C19 polymorphisms on clopidogrel response.

Clinical pharmacology : advances and applications

Kreutz RP, Nystrom P, Kreutz Y, Miao J, Desta Z, Breall JA, Li L, Chiang C, Kovacs R, Flockhart DA, Jin Y.
PMID: 22427735
Clin Pharmacol. 2012;4:13-20. doi: 10.2147/CPAA.S27822. Epub 2012 Feb 20.

BACKGROUND: The metabolic activation of clopidogrel is a two-step process. It has been suggested that paraoxonase-1 (PON1) is a rate-limiting enzyme in the conversion of 2-oxo- clopidogrel to an active thiol metabolite. Conflicting results have been reported in regard...

Cite
Kreutz RP, Nystrom P, Kreutz Y, et al. Influence of paraoxonase-1 Q192R and cytochrome P450 2C19 polymorphisms on clopidogrel response. Clin Pharmacol. 2012;4:13-20doi: 10.2147/CPAA.S27822.
Kreutz, R. P., Nystrom, P., Kreutz, Y., Miao, J., Desta, Z., Breall, J. A., Li, L., Chiang, C., Kovacs, R., Flockhart, D. A., & Jin, Y. (2012). Influence of paraoxonase-1 Q192R and cytochrome P450 2C19 polymorphisms on clopidogrel response. Clinical pharmacology : advances and applications, 413-20. https://doi.org/10.2147/CPAA.S27822
Kreutz, Rolf P, et al. "Influence of paraoxonase-1 Q192R and cytochrome P450 2C19 polymorphisms on clopidogrel response." Clinical pharmacology : advances and applications vol. 4 (2012): 13-20. doi: https://doi.org/10.2147/CPAA.S27822
Kreutz RP, Nystrom P, Kreutz Y, Miao J, Desta Z, Breall JA, Li L, Chiang C, Kovacs R, Flockhart DA, Jin Y. Influence of paraoxonase-1 Q192R and cytochrome P450 2C19 polymorphisms on clopidogrel response. Clin Pharmacol. 2012;4:13-20. doi: 10.2147/CPAA.S27822. Epub 2012 Feb 20. PMID: 22427735; PMCID: PMC3304338.
Copy Download .nbib Format: NLM
Measurement of a sign-changing two-gap superconducting phase in electron-doped Ba(Fe(1-x)Co(x))2As2 single crystals using scanning tunneling spectroscopy.

Physical review letters

Teague ML, Drayna GK, Lockhart GP, Cheng P, Shen B, Wen HH, Yeh NC.
PMID: 21405593
Phys Rev Lett. 2011 Feb 25;106(8):087004. doi: 10.1103/PhysRevLett.106.087004. Epub 2011 Feb 24.

Scanning tunneling spectroscopic studies of Ba(Fe(1-x)Co(x))(2)As(2) (x=0.06, 0.12) single crystals reveal direct evidence for predominantly two-gap superconductivity. These gaps decrease with increasing temperature and vanish above the superconducting transition T(c). The two-gap nature and the slightly doping- and energy-dependent...

Cite
Teague ML, Drayna GK, Lockhart GP, et al. Measurement of a sign-changing two-gap superconducting phase in electron-doped Ba(Fe(1-x)Co(x))2As2 single crystals using scanning tunneling spectroscopy. Phys Rev Lett. 2011;106(8):087004doi: 10.1103/PhysRevLett.106.087004.
Teague, M. L., Drayna, G. K., Lockhart, G. P., Cheng, P., Shen, B., Wen, H. H., & Yeh, N. C. (2011). Measurement of a sign-changing two-gap superconducting phase in electron-doped Ba(Fe(1-x)Co(x))2As2 single crystals using scanning tunneling spectroscopy. Physical review letters, 106(8), 087004. https://doi.org/10.1103/PhysRevLett.106.087004
Teague, M L, et al. "Measurement of a sign-changing two-gap superconducting phase in electron-doped Ba(Fe(1-x)Co(x))2As2 single crystals using scanning tunneling spectroscopy." Physical review letters vol. 106,8 (2011): 087004. doi: https://doi.org/10.1103/PhysRevLett.106.087004
Teague ML, Drayna GK, Lockhart GP, Cheng P, Shen B, Wen HH, Yeh NC. Measurement of a sign-changing two-gap superconducting phase in electron-doped Ba(Fe(1-x)Co(x))2As2 single crystals using scanning tunneling spectroscopy. Phys Rev Lett. 2011 Feb 25;106(8):087004. doi: 10.1103/PhysRevLett.106.087004. Epub 2011 Feb 24. PMID: 21405593.
Copy Download .nbib Format: NLM
Impact of the Interaction between 3'-UTR SNPs and microRNA on the Expression of Human Xenobiotic Metabolism Enzyme and Transporter Genes.

Frontiers in genetics

Wei R, Yang F, Urban TJ, Li L, Chalasani N, Flockhart DA, Liu W.
PMID: 23181071
Front Genet. 2012 Nov 21;3:248. doi: 10.3389/fgene.2012.00248. eCollection 2012.

Genetic variation in the expression of human xenobiotic metabolism enzymes and transporters (XMETs) leads to inter-individual variability in metabolism of therapeutic agents as well as differed susceptibility to various diseases. Recent expression quantitative traits loci (eQTL) mapping in a...

Cite
Wei R, Yang F, Urban TJ, et al. Impact of the Interaction between 3'-UTR SNPs and microRNA on the Expression of Human Xenobiotic Metabolism Enzyme and Transporter Genes. Front Genet. 2012;3:248doi: 10.3389/fgene.2012.00248.
Wei, R., Yang, F., Urban, T. J., Li, L., Chalasani, N., Flockhart, D. A., & Liu, W. (2012). Impact of the Interaction between 3'-UTR SNPs and microRNA on the Expression of Human Xenobiotic Metabolism Enzyme and Transporter Genes. Frontiers in genetics, 3248. https://doi.org/10.3389/fgene.2012.00248
Wei, Rongrong, et al. "Impact of the Interaction between 3'-UTR SNPs and microRNA on the Expression of Human Xenobiotic Metabolism Enzyme and Transporter Genes." Frontiers in genetics vol. 3 (2012): 248. doi: https://doi.org/10.3389/fgene.2012.00248
Wei R, Yang F, Urban TJ, Li L, Chalasani N, Flockhart DA, Liu W. Impact of the Interaction between 3'-UTR SNPs and microRNA on the Expression of Human Xenobiotic Metabolism Enzyme and Transporter Genes. Front Genet. 2012 Nov 21;3:248. doi: 10.3389/fgene.2012.00248. eCollection 2012. PMID: 23181071; PMCID: PMC3502871.
Copy Download .nbib Format: NLM
Barriers and facilitators to conduct high-quality, large-scale safety and comparative effectiveness research: The Biologics and Biosimilars Collective Intelligence Consortium experience.

Pharmacoepidemiology and drug safety

Lockhart CM, McDermott CL, Felix T, Lin ND, Cziraky MJ, Mendelsohn AB, Brown JS.
PMID: 31402533
Pharmacoepidemiol Drug Saf. 2020 Jul;29(7):811-813. doi: 10.1002/pds.4885. Epub 2019 Aug 11.

No abstract available.

Cite
Lockhart CM, McDermott CL, Felix T, et al. Barriers and facilitators to conduct high-quality, large-scale safety and comparative effectiveness research: The Biologics and Biosimilars Collective Intelligence Consortium experience. Pharmacoepidemiol Drug Saf. 2019;29(7):811-813doi: 10.1002/pds.4885.
Lockhart, C. M., McDermott, C. L., Felix, T., Lin, N. D., Cziraky, M. J., Mendelsohn, A. B., & Brown, J. S. (2020). Barriers and facilitators to conduct high-quality, large-scale safety and comparative effectiveness research: The Biologics and Biosimilars Collective Intelligence Consortium experience. Pharmacoepidemiology and drug safety, 29(7), 811-813. https://doi.org/10.1002/pds.4885
Lockhart, Catherine M, et al. "Barriers and facilitators to conduct high-quality, large-scale safety and comparative effectiveness research: The Biologics and Biosimilars Collective Intelligence Consortium experience." Pharmacoepidemiology and drug safety vol. 29,7 (2020): 811-813. doi: https://doi.org/10.1002/pds.4885
Lockhart CM, McDermott CL, Felix T, Lin ND, Cziraky MJ, Mendelsohn AB, Brown JS. Barriers and facilitators to conduct high-quality, large-scale safety and comparative effectiveness research: The Biologics and Biosimilars Collective Intelligence Consortium experience. Pharmacoepidemiol Drug Saf. 2020 Jul;29(7):811-813. doi: 10.1002/pds.4885. Epub 2019 Aug 11. PMID: 31402533.
Copy Download .nbib Format: NLM
When Two Pandemics Meet: Why Is Obesity Associated with Increased COVID-19 Mortality?.

Med (New York, N.Y.)

Lockhart SM, O'Rahilly S.
PMID: 32838359
Med (N Y). 2020 Dec 18;1(1):33-42. doi: 10.1016/j.medj.2020.06.005. Epub 2020 Jun 29.

A growing body of evidence indicates that obesity is strongly and independently associated with adverse outcomes of COVID-19, including death. By combining emerging knowledge of the pathological processes involved in COVID-19 with insights into the mechanisms underlying the adverse...

Cite
Lockhart SM, O'Rahilly S. When Two Pandemics Meet: Why Is Obesity Associated with Increased COVID-19 Mortality?. Med (N Y). 2020;1(1):33-42doi: 10.1016/j.medj.2020.06.005.
Lockhart, S. M., & O'Rahilly, S. (2020). When Two Pandemics Meet: Why Is Obesity Associated with Increased COVID-19 Mortality?. Med (New York, N.Y.), 1(1), 33-42. https://doi.org/10.1016/j.medj.2020.06.005
Lockhart, Sam M, and O'Rahilly, Stephen. "When Two Pandemics Meet: Why Is Obesity Associated with Increased COVID-19 Mortality?." Med (New York, N.Y.) vol. 1,1 (2020): 33-42. doi: https://doi.org/10.1016/j.medj.2020.06.005
Lockhart SM, O'Rahilly S. When Two Pandemics Meet: Why Is Obesity Associated with Increased COVID-19 Mortality?. Med (N Y). 2020 Dec 18;1(1):33-42. doi: 10.1016/j.medj.2020.06.005. Epub 2020 Jun 29. PMID: 32838359; PMCID: PMC7323660.
Copy Download .nbib Format: NLM
ACE inhibition and cardiometabolic risk factors, lung .

Royal Society open science

Gill D, Arvanitis M, Carter P, Hernández Cordero AI, Jo B, Karhunen V, Larsson SC, Li X, Lockhart SM, Mason A, Pashos E, Saha A, Tan VY, Zuber V, Bossé Y, Fahle S, Hao K, Jiang T, Joubert P, Lunt AC, Ouwehand WH, Roberts DJ, Timens W, van den Berge M, Watkins NA, Battle A, Butterworth AS, Danesh J, Di Angelantonio E, Engelhardt BE, Peters JE, Sin DD, Burgess S.
PMID: 33391794
R Soc Open Sci. 2020 Nov 18;7(11):200958. doi: 10.1098/rsos.200958. eCollection 2020 Nov.

Angiotensin-converting enzyme 2 (ACE2) and serine protease TMPRSS2 have been implicated in cell entry for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus responsible for coronavirus disease 2019 (COVID-19). The expression of

Cite
Gill D, Arvanitis M, Carter P, et al. ACE inhibition and cardiometabolic risk factors, lung . R Soc Open Sci. 2020;7(11):200958doi: 10.1098/rsos.200958.
Gill, D., Arvanitis, M., Carter, P., Hernández Cordero, A. I., Jo, B., Karhunen, V., Larsson, S. C., Li, X., Lockhart, S. M., Mason, A., Pashos, E., Saha, A., Tan, V. Y., Zuber, V., Bossé, Y., Fahle, S., Hao, K., Jiang, T., Joubert, P., Lunt, A. C., Ouwehand, W. H., Roberts, D. J., Timens, W., van den Berge, M., Watkins, N. A., Battle, A., Butterworth, A. S., Danesh, J., Di Angelantonio, E., Engelhardt, B. E., Peters, J. E., Sin, D. D., & Burgess, S. (2020). ACE inhibition and cardiometabolic risk factors, lung . Royal Society open science, 7(11), 200958. https://doi.org/10.1098/rsos.200958
Gill, Dipender, et al. "ACE inhibition and cardiometabolic risk factors, lung ." Royal Society open science vol. 7,11 (2020): 200958. doi: https://doi.org/10.1098/rsos.200958
Gill D, Arvanitis M, Carter P, Hernández Cordero AI, Jo B, Karhunen V, Larsson SC, Li X, Lockhart SM, Mason A, Pashos E, Saha A, Tan VY, Zuber V, Bossé Y, Fahle S, Hao K, Jiang T, Joubert P, Lunt AC, Ouwehand WH, Roberts DJ, Timens W, van den Berge M, Watkins NA, Battle A, Butterworth AS, Danesh J, Di Angelantonio E, Engelhardt BE, Peters JE, Sin DD, Burgess S. ACE inhibition and cardiometabolic risk factors, lung . R Soc Open Sci. 2020 Nov 18;7(11):200958. doi: 10.1098/rsos.200958. eCollection 2020 Nov. PMID: 33391794; PMCID: PMC7735342.
Copy Download .nbib Format: NLM
Methodologic considerations for noninterventional studies of switching from reference biologic to biosimilars.

Pharmacoepidemiology and drug safety

Desai RJ, Kim SC, Curtis JR, Bosco JLF, Eichelberger B, Barr CE, Lockhart CM, Bradbury BD, Clewell J, Cohen HP, Gagne JJ.
PMID: 31298463
Pharmacoepidemiol Drug Saf. 2020 Jul;29(7):757-769. doi: 10.1002/pds.4809. Epub 2019 Jul 12.

PURPOSE: As more biosimilars become available in the United States, postapproval noninterventional studies describing biosimilar switching and comparing effectiveness and/or safety between switchers and nonswitchers will play a key role in generating real-world evidence to inform clinical practices and...

Cite
Desai RJ, Kim SC, Curtis JR, et al. Methodologic considerations for noninterventional studies of switching from reference biologic to biosimilars. Pharmacoepidemiol Drug Saf. 2019;29(7):757-769doi: 10.1002/pds.4809.
Desai, R. J., Kim, S. C., Curtis, J. R., Bosco, J. L. F., Eichelberger, B., Barr, C. E., Lockhart, C. M., Bradbury, B. D., Clewell, J., Cohen, H. P., Gagne, J. J. (2020). Methodologic considerations for noninterventional studies of switching from reference biologic to biosimilars. Pharmacoepidemiology and drug safety, 29(7), 757-769. https://doi.org/10.1002/pds.4809
Desai, Rishi J, et al. "Methodologic considerations for noninterventional studies of switching from reference biologic to biosimilars." Pharmacoepidemiology and drug safety vol. 29,7 (2020): 757-769. doi: https://doi.org/10.1002/pds.4809
Desai RJ, Kim SC, Curtis JR, Bosco JLF, Eichelberger B, Barr CE, Lockhart CM, Bradbury BD, Clewell J, Cohen HP, Gagne JJ. Methodologic considerations for noninterventional studies of switching from reference biologic to biosimilars. Pharmacoepidemiol Drug Saf. 2020 Jul;29(7):757-769. doi: 10.1002/pds.4809. Epub 2019 Jul 12. PMID: 31298463.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 73 entries